Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models.

[1]  E. Perez,et al.  Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Olmos.  Multi-institutional prognostic factor analysis of patients (pts) enrolled in phase I (Ph I) oncology trials: Can pts selection be improved? , 2010 .

[3]  J. Blay,et al.  Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics , 2010, Investigational New Drugs.

[4]  David Olmos,et al.  Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Lippman,et al.  The changing face of Phase 1 cancer clinical trials , 2009, Cancer.

[6]  R. Kurzrock,et al.  Survival of patients in a Phase 1 clinic , 2009, Cancer.

[7]  R. Kurzrock,et al.  Risks and benefits of phase 1 oncology trials, revisited. , 2005, The New England journal of medicine.

[8]  I. Judson,et al.  90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? , 2008, European journal of cancer.

[9]  J. Bonneterre,et al.  Prognostic factors among cancer patients with good performance status screened for phase I trials , 2008, Investigational New Drugs.

[10]  J. Bono,et al.  Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience , 2007, British Journal of Cancer.

[11]  S. Faivre,et al.  Méthodologie des essais de phase I en cancérologie , 2007 .

[12]  N. Normanno,et al.  Methodology of clinical trials with new molecular-targeted agents: where do we stand? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Edward L Korn,et al.  Dose escalation trial designs based on a molecularly targeted endpoint , 2005, Statistics in medicine.

[14]  Seiichiro Yamamoto,et al.  Risks and benefits of phase 1 oncology trials, 1991 through 2002. , 2005, The New England journal of medicine.

[15]  Elkan F Halpern,et al.  Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. , 2004, JAMA.

[16]  E. Eisenhauer,et al.  Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. , 2004, Journal of the National Cancer Institute.

[17]  A. Harris,et al.  Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents , 2003, British Journal of Cancer.

[18]  M. Christian,et al.  Phase I clinical trial design in cancer drug development. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Verweij.  The prognosis of prognostic factors in phase I clinical trials. , 2000, Annals of Oncology.

[20]  I. Ray-Coquard,et al.  Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  N. Saijo,et al.  Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. , 1999, International journal of oncology.

[22]  E. Eisenhauer,et al.  Phase I trial design: are new methodologies being put into practice? , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. Schilsky,et al.  Prognostic factors for survival in patients treated in phase I clinical trials , 1994, Cancer.

[24]  N. Magné,et al.  Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  G. Giaccone,et al.  Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). , 2008, European journal of cancer.